Piperacillin-tazobactam — Competitive Intelligence Brief

Piperacillin-tazobactam (Piperacillin-tazobactam) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic with beta-lactamase inhibitor. Area: Infectious Disease.

marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); beta-lactamases Infectious Disease Small molecule

Target snapshot

Piperacillin-tazobactam (Piperacillin-tazobactam) — University Hospital, Bordeaux. Piperacillin-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Piperacillin-tazobactam TARGET	Piperacillin-tazobactam	University Hospital, Bordeaux	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamases
Amoxicillin-Potassium Clavulanate Combination	Amoxicillin-Potassium Clavulanate Combination	Universidad Complutense de Madrid	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
ampicillin/clavulanate	ampicillin/clavulanate	Phoenix Children's Hospital	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxycillin/clavulanic acid	Amoxycillin/clavulanic acid	TASK Applied Science	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
amoxicillin/clavulanate potassium 1gm	amoxicillin/clavulanate potassium 1gm	GlaxoSmithKline	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
Amoxicillin potassium clavulanate	Amoxicillin potassium clavulanate	Kaizen Bioscience Co.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxicillin clavulanic	Amoxicillin clavulanic	Hospital Italiano de Buenos Aires	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic with beta-lactamase inhibitor class)

1. Medical University of Vienna · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Phoenix Children's Hospital · 2 drugs in this class
4. Albany Medical College · 2 drugs in this class
5. Pfizer · 2 drugs in this class
6. Imperial College London · 1 drug in this class
7. Hospital Italiano de Buenos Aires · 1 drug in this class
8. Bayer · 1 drug in this class
9. Maggiore Bellaria Hospital, Bologna · 1 drug in this class
10. Kaizen Bioscience Co. · 1 drug in this class